Literature DB >> 11577167

Molecular genetics of solid tumours: translating research into clinical practice. What we could do now: breast cancer.

S R Lakhani1.   

Abstract

Breast cancer is a common solid malignancy in women. Over the past decade, much progress has been made in understanding the biology of breast cancer. The use of molecular and immunohistochemical techniques is providing insights that will allow us to tailor the management of patients with breast cancer. In this review, progress in the understanding of lobular carcinoma in situ and atypical ductal hyperplasia, the use of the molecular marker CerbB2, and information gained from the morphological analysis of tumours arising in patients with BRCA1 and BRCA2 mutations is discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11577167      PMCID: PMC1187082          DOI: 10.1136/mp.54.5.281

Source DB:  PubMed          Journal:  Mol Pathol        ISSN: 1366-8714


  59 in total

1.  Causes of inconsistency in diagnosing and classifying intraductal proliferations of the breast. European Commission Working Group on Breast Screening Pathology.

Authors:  C W Elston; J P Sloane; I Amendoeira; N Apostolikas; J P Bellocq; S Bianchi; W Boecker; G Bussolati; D Coleman; C E Connolly; P Dervan; M Drijkoningen; V Eusebi; D Faverly; R Holland; J Jacquemier; M Lacerda; J Martinez-Penuela; C de Miguel; S Mossi; C Munt; J L Peterse; F Rank; A Reiner; M Sylvan; C A Wells; B Zafrani
Journal:  Eur J Cancer       Date:  2000-09       Impact factor: 9.162

2.  Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci.

Authors:  P O'Connell; V Pekkel; S A Fuqua; C K Osborne; G M Clark; D C Allred
Journal:  J Natl Cancer Inst       Date:  1998-05-06       Impact factor: 13.506

3.  Hormone status of in-situ cancer in BRCA1 and BRCA2 mutation carriers.

Authors:  P Osin; T Crook; T Powles; J Peto; B Gusterson
Journal:  Lancet       Date:  1998-05-16       Impact factor: 79.321

4.  Noninvasive breast carcinoma: frequency of unsuspected invasion and implications for treatment.

Authors:  P P Rosen; R Senie; D Schottenfeld; R Ashikari
Journal:  Ann Surg       Date:  1979-03       Impact factor: 12.969

5.  Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

Authors:  M D Pegram; A Lipton; D F Hayes; B L Weber; J M Baselga; D Tripathy; D Baly; S A Baughman; T Twaddell; J A Glaspy; D J Slamon
Journal:  J Clin Oncol       Date:  1998-08       Impact factor: 44.544

6.  Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas.

Authors:  R Moll; M Mitze; U H Frixen; W Birchmeier
Journal:  Am J Pathol       Date:  1993-12       Impact factor: 4.307

7.  Precancerous and cancerous breast lesions during lifetime and at autopsy. A study of 83 women.

Authors:  M Nielsen; J Jensen; J Andersen
Journal:  Cancer       Date:  1984-08-15       Impact factor: 6.860

8.  Consistency of histopathological reporting of breast lesions detected by screening: findings of the U.K. National External Quality Assessment (EQA) Scheme. U. K. National Coordinating Group for Breast Screening Pathology.

Authors:  J P Sloane; R Ellman; T J Anderson; C L Brown; J Coyne; N S Dallimore; J D Davies; D Eakins; I O Ellis; C W Elston
Journal:  Eur J Cancer       Date:  1994       Impact factor: 9.162

9.  c-erbB-2 expression in benign and malignant breast disease.

Authors:  B A Gusterson; L G Machin; W J Gullick; N M Gibbs; T J Powles; C Elliott; S Ashley; P Monaghan; S Harrison
Journal:  Br J Cancer       Date:  1988-10       Impact factor: 7.640

10.  E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis.

Authors:  C B Vos; A M Cleton-Jansen; G Berx; W J de Leeuw; N T ter Haar; F van Roy; C J Cornelisse; J L Peterse; M J van de Vijver
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more
  4 in total

Review 1.  Methods of molecular analysis: assessing losses and gains in tumours.

Authors:  R Roylance
Journal:  Mol Pathol       Date:  2002-02

2.  Anaplastic lymphoma kinase is expressed in different subtypes of human breast cancer.

Authors:  Pablo Perez-Pinera; Y Chang; A Astudillo; J Mortimer; T F Deuel
Journal:  Biochem Biophys Res Commun       Date:  2007-04-30       Impact factor: 3.575

3.  Molecular evidence for putative tumour suppressor genes on chromosome 13q specific to BRCA1 related ovarian and fallopian tube cancer.

Authors:  A P M Jongsma; J M J Piek; R P Zweemer; R H M Verheijen; J W T Klein Gebbinck; G J van Kamp; I J Jacobs; P Shaw; P J van Diest; P Kenemans
Journal:  Mol Pathol       Date:  2002-10

4.  Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype.

Authors:  A Mitra; C Fisher; C S Foster; C Jameson; Y Barbachanno; J Bartlett; E Bancroft; R Doherty; Z Kote-Jarai; S Peock; D Easton; R Eeles
Journal:  Br J Cancer       Date:  2008-01-08       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.